Clinical trial NCT02597075: Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy
Official title: Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy. A Multicenter Open Label Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Metastatic Colorectal Cancer
Keywords: Colorectal Cancer
Metastatic Colorectal Cancer
Physical Activity
Quality of life
Lead sponsor: Swiss Group for Clinical Cancer Research
Sponsor class: OTHER
First posted: 2015-11-04
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess whether a structured physical activity program (PA) during palliative chemotherapy improves progression-free survival (PFS) and/or patient-reported outcomes (ESAS-r) in patients with metastatic colorectal cancer.

Detailed description: While safety and feasibility as well as some improvements in fitness, fatigue and certain aspects of quality of life have been shown for physical activity in cancer patients during treatment, none of the pre-requisites above (i-iv) is fulfilled in the setting of patients with advanced colon cancer.

However, evidence, primarily from the adjuvant setting, that physical activity impacts on treatment tolerability and tumor progression is a strong enough rationale to now embark on this prospective trial. By assessing in a large randomized controlled trial whether a 12-week structured physical activity program during chemotherapy in patients with newly diagnosed colorectal cancer undergoing standard first-line chemotherapy improves progression-free survival as compared to standard first-line chemotherapy alone, all pre-requisites for a practice-changing intervention are met.

The physical exercise ACTIVE-program describes a 12-week exercise program consisting of a combination of a bi-weekly aerobic exercise (cycle ergometer) supervised by a physical therapist and a self-paced increase in physical activity during daily life using a pedometer with a daily step goal as a motivational tool.

In addition to the supervised exercise program twice a week, patients of the intervention group are recommended to be physically active at home.

All patients will undergo standard systemic therapy for metastatic colorectal cancer. Patients in the care-as-usual group are not actively encouraged to change their physical activity level e.g. to start a fitness program during chemotherapy.

Eligibility criteria: Inclusion Criteria:

* Written informed consent according to ICH/GCP regulations before randomization.
* Patient with histologically or cytologically confirmed colorectal carcinoma (CRC) who start palliative first-line systemic therapy for inoperable or metastatic disease.

Note: Patients can be included before the start or within the first three weeks of first-line systemic treatment.

* Patients with histologically or cytologically confirmed colorectal carcinoma (CRC), who start first-line "conversion"-therapy for borderline resectable metastatic disease and will be reassessed for metastasectomy after 3-4 months of systemic treatment.

Note: Patients can be included before the start or within the first three weeks of first-line systemic treatment.

Patients who are diagnosed with metastatic disease and were initially treated with surgery and/or radiochemotherapy to the primary tumor are eligible (except if all disease sites/metastases have been removed) Patients who have been curatively treated with histologically or cytologically confirmed nonmetastatic CRC previously and now relapse with metastatic disease are also eligible, irrespective of previous radiochemotherapy and/or adjuvant chemotherapy

* Patients must have measurable disease on CT scan or MRI to be performed within 6 weeks before randomization (measurability criteria according to RECIST 1.1, non-nodal lesions ≥10 mm, lymph nodes ≥15mm) OR evaluable disease i.e. patient with nonmeasurable metastases but elevated serum tumor-marker (CEA at least \>2xULN).
* Command of written and spoken language allowing for informed consent and for filling in trial questionnaires.
* Baseline patient-reported outcomes (PROs) have been completed.
* WHO performance status 0-2.
* Age ≥18 years

Exclusion Criteria:

* Pre-existing severe medical conditions precluding participation in a physical activity program as determined by the local investigator. Such conditions include: chronic heart failure (greater than NYHA II), recent myocardial infarction (less than 3 months ago), unstable angina pectoris, clinically significant arrhythmias, uncontrolled hypertension with repeated systolic blood pressure above 160mmHg, and COPD (requiring oxygen supply or GOLD stadium greater than 2).
* Inability to ride a cycle ergometer e.g. for musculoskeletal reasons.
* Patients in whom all CRC metastases have been removed surgically. It is allowed to include patients for whom metastasectomy might be an option if chemotherapy induces a significant response.
* Any serious underlying medical condition (at the judgment of the investigator) which could impair the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes).
* Concurrent treatment in a trial with experimental drugs or other anti-cancer therapy, which are hypothesized to alter tumor progression. Participation in an observational trial or a translational trial is allowed. Palliative radiotherapy is allowed.
* Psychiatric disorder precluding understanding of trial information, giving informed consent, filling out PRO forms, or interfering with compliance.
* Any psychological, familial, sociological or geographical condition potentially hampering proper compliance with the trial protocol.

Primary outcomes:
measure: Progression-free survival (PFS)
timeFrame: every 8 or 9 weeks during one year
measure: Change in Patient-reported symptoms as measured by ESAS-r
timeFrame: in at week 6, 12, 18, 24, 48
Secondary outcomes:
measure: Overall survival
timeFrame: after progression (expected 1 year) lifelong follow-up
measure: Best Objective Response
timeFrame: at week 8 or 9 during one year
measure: Selected adverse events
timeFrame: day 1 of each cycle (every 8 or 9 weeks)
measure: Chemotherapy-completion-rate
timeFrame: week 6, 12, 18, and 24
measure: Initiation or increase of anti-hypertensive drugs
timeFrame: day 1 of each cycle (every 8 or 9 weeks) for one year
Other outcomes:
Locations:
city: Salzburg
country: Austria
facility: Universitätsklinikum der PMU Salzburg
city: Wels
country: Austria
facility: Klinikum Wels-Grieskirchen GmbH
city: Aarau
country: Switzerland
facility: Tumor Zentrum Aarau
city: Aarau
country: Switzerland
facility: Kantonsspital Aarau
city: Baden
country: Switzerland
facility: Kantonsspital Baden
city: Basel
country: Switzerland
facility: St. Claraspital
city: Basel
country: Switzerland
facility: Clinical Cancer Research Center at University Hospital Basel
city: Bellinzona
country: Switzerland
facility: Istituto Oncologico della Svizzera Italiana IOSI
city: Biel
country: Switzerland
facility: Spitalzentrum Biel
city: Brig
country: Switzerland
facility: Spitalzentrum Oberwallis
city: Chur
country: Switzerland
facility: Kantonsspital Graubünden
city: Fribourg
country: Switzerland
facility: Hôpital Fribourgeois HFR
city: Genève 14
country: Switzerland
facility: Hôpitaux Universitaires de Genève
city: Lausanne
country: Switzerland
facility: Centre de Chimiothérapie Anti-Cancéreuse
city: Liestal
country: Switzerland
facility: Kantonsspital Baselland
city: Luzern
country: Switzerland
facility: Kantonsspital Luzern
city: Münsterlingen
country: Switzerland
facility: Spital Thurgau
city: Olten
country: Switzerland
facility: Kantonsspital Olten
city: St. Gallen
country: Switzerland
facility: Kantonsspital - St. Gallen
city: Thun
country: Switzerland
facility: SpitalSTS AG Simmental-Thun-Saanenland
city: Zurich
country: Switzerland
facility: Onkozentrum - Klinik im Park
city: Zurich
country: Switzerland
facility: UniversitätsSpital Zurich
city: Zürich
country: Switzerland
facility: Onkozentrum Hirslanden Zürich
city: Zürich
country: Switzerland
facility: Stadtspital Triemli
Study officials:
affiliation: University Hospital, Basel, Switzerland
name: Viviane Hess, Prof Dr med
role: STUDY_CHAIR
References: